Applied Therapeutics Inc(APLT)stock report

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.

Finance:
Market Cap:858.3M; Shares Outstanding:18.5M; Short Interest: 2.07%; Q3 2019(9/30/19): Cash 32.95M. Loss 10.71M

EPS and Sales:
https://finance.yahoo.com/quote/APLT/financials?p=APLT

Date EPS % last year % last quarter
2018.12.31 -3.01 -281.01% -68.16%
2019.3.31 -1.58 -267.44% 47.51%
2019.6.30 -1.76 -74.26% -11.39%
2019.9.30 -1.98 -10.61% -12.50%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=APLT&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/APLT/institutional-ownership/

2020.01.15:
Total institutions: 33,no change
Shares hold: 2395.9k shares. no change
shares% hold: 12.94%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/APLT/price-targe

Leave a Reply